Replies to post #804191 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

There is only one company on this planet that solely owns the technology that can make DCs present hundreds of tumor-associated peptides to immune system so that massive and sustainable t-cell infiltration into tumor site can be activated.

OK, let us discuss it.

There is no question that all ATL based DC vaccines are about the same. They take monocytes from the patients blood, differentiate into immature DCs, then activate them in presence of the tumor to hopefully obtain DCs that when injected back into the patient to hopefully get the immune system going.

The basic technology was used by many as far back as 1995. NWBO did come up with one enhancement. While others had been using acid baths to extract the lysate from the tumor, NWBO was using freeze/thaw cycles to accomplish this. I think NWBO was the first to do this, and is in their patent from 2001.

But that is all from 25 years ago. Anybody can do this now.

And more importantly, any ATL DC is going to show the same features of presenting hundreds of tumor associated antigens. It is what they do in life. That you think NWBO has something special in this is a complete failure to understand.

Maybe NWBO really does have some small twist on the process that makes their version work better. But if so, given how similar the others are, it is likely very marginal. Further, the idea BP couldn't do this is naive. Whatever process NWBO used has been replicated by multiple parties over 2 decades. It is not going to be some secret formula.

More likely NWBO has nothing other than what all the ATL DCs have. A marginal product that might work, but is commercially a "meh": due to marginal effectiveness and high cost.